Hookipa Pharma (HOOK) Scheduled to Post Quarterly Earnings on Thursday

Hookipa Pharma (NASDAQ:HOOK) is set to release its earnings data before the market opens on Thursday, May 9th. Analysts expect Hookipa Pharma to post earnings of ($0.12) per share for the quarter.

Hookipa Pharma (NASDAQ:HOOK) last announced its quarterly earnings data on Friday, March 22nd. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.09. Hookipa Pharma had a negative return on equity of 72.30% and a negative net margin of 405.28%. The company had revenue of $7.41 million for the quarter, compared to analyst estimates of $3.60 million. On average, analysts expect Hookipa Pharma to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Hookipa Pharma Stock Up 2.7 %

Hookipa Pharma stock opened at $0.85 on Wednesday. The company has a fifty day simple moving average of $0.78 and a 200-day simple moving average of $0.68. The firm has a market capitalization of $84.08 million, a price-to-earnings ratio of -0.94 and a beta of 0.92. Hookipa Pharma has a 52-week low of $0.41 and a 52-week high of $2.05.

Wall Street Analysts Forecast Growth

HOOK has been the topic of a number of research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $5.00 target price on shares of Hookipa Pharma in a research note on Monday, March 25th. HC Wainwright lowered their price objective on Hookipa Pharma from $6.50 to $5.00 and set a “buy” rating on the stock in a research note on Friday, April 26th.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.